https://pharmadevicenews.com/pulse-biosciences-plse-reports-86-thyroid-nodule-response-but-can-the-results-hold/ PharmaDeviceNews en 2026-11-06T13:45:40+00:00 Pulse Biosciences (PLSE) reports 86% thyroid nodule response, but can the results hold? American Thyroid Association, Clayman Thyroid Center, Kepal Patel, nPulse Vybrance Percutaneous Electrode System, NYU Langone Health, Paul LaViolette, PRECISE-BTN, Pulse Biosciences, Ralph Tufano, Sarasota Memorial Health Care System, Thomas Fahey, Weill Cornell Medicine https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp https://pharmadevicenews.com/network-bios-duke-university-deal-targets-a-critical-gap-in-medical-ai-what-happened-to-patients/ PharmaDeviceNews en 2026-11-06T13:41:42+00:00 Network Bio’s Duke University deal targets a critical gap in medical AI: What happened to patients? Asad Ali Ahmad, Duke Center for Precision Health, Duke University, Duke University School of Medicine, Mass General Brigham, Network Bio, NVIDIA, Raphael Potter, Svati H. Shah, University of Colorado Anschutz, University of Pennsylvania https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-research-lab.webp https://pharmadevicenews.com/fda-fast-track-for-frp-003-can-front-range-pharmaceuticals-tackle-long-covid-fatigue/ PharmaDeviceNews en 2026-11-06T13:38:10+00:00 FDA Fast Track for FRP-003: Can Front Range Pharmaceuticals tackle Long COVID fatigue? Front Range Pharmaceuticals, FRP-003, Isaac Foster, Long COVID, Suzanne Vernon, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/06/AMDIs-rapid-respiratory-panel-clears-the-FDA-as-point-of-care-PCR-competition-intensifies-e1781963612772.webp https://pharmadevicenews.com/ge-healthcare-backs-laza-medical-with-a-potential-160m-investment-but-can-robotic-ultrasound-transform-the-cath-lab/ PharmaDeviceNews en 2026-11-06T13:19:36+00:00 GE HealthCare backs LAZA Medical with a potential $160m investment, but can robotic ultrasound transform the cath lab? AMED, Amr Salahieh, Firas Zahr, GE HealthCare Technologies, Jyoti Gera, LAZA Medical, Los Gatos, Oregon Health & Science University, PA MedTech, Shifamed, Unorthodox Ventures https://pharmadevicenews.com/wp-content/uploads/2026/07/Dopl-Technologies-targets-FDA-clearance-for-remote-robotic-ultrasound-ecosystem-e1785175245650.webp https://pharmadevicenews.com/how-verismos-multi-chain-kir-car-platform-differs-from-conventional-car-t/ PharmaDeviceNews en 2026-11-06T13:15:09+00:00 How Verismo’s multi-chain KIR-CAR platform differs from conventional CAR-T American Society of Hematology, Brian Kim, CELESTIAL-301, Colorado Blood Cancer Institute, HLB Innovation, Michael Tees, SynKIR-310, Verismo Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/01/lymphoma-research.webp https://pharmadevicenews.com/emergent-biosolutions-wins-22-3m-biothrax-order-as-us-military-maintains-anthrax-preparedness/ PharmaDeviceNews en 2026-11-06T13:10:25+00:00 Emergent BioSolutions wins $22.3m BioThrax order as US military maintains anthrax preparedness Biomedical Advanced Research and Development Authority, BioThrax, CYFENDUS, Defense Health Agency, Emergent BioSolutions, Joe Papa, Paul Williams, United States Department of War https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/innovivas-antibiotics-are-growing-45-so-why-did-the-company-report-a-73-9m-loss/ PharmaDeviceNews en 2026-11-05T04:16:52+00:00 Innoviva’s antibiotics are growing 45%, so why did the company report a $73.9m loss? Armata Pharmaceuticals, Basilea Pharmaceutica, Entasis Therapeutics, GIAPREZA, GSK, Innoviva Inc., Innoviva Specialty Therapeutics, NUZOLVENCE, Pavel Raifeld, XACDURO, XERAVA, ZEVTERA https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/summit-therapeutics-has-2bn-from-astrazeneca-and-stronger-cancer-survival-data-but-will-the-fda-approve-ivonescimab/ PharmaDeviceNews en 2026-11-05T04:12:47+00:00 Summit Therapeutics has $2bn from AstraZeneca and stronger cancer survival data, but will the FDA approve ivonescimab? Akeso, AstraZeneca, Daiichi Sankyo, Datroway, HARMONi, HARMONi-2, HARMONi-3, HARMONi-7, Ivonescimab, Maky Zanganeh, Robert W. Duggan, Summit Therapeutics Inc. https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/evommune-bets-30m-on-a-vav1-degrader-that-could-challenge-jak-inhibitors-but-can-it-deliver-safer-autoimmune-treatment/ PharmaDeviceNews en 2026-11-05T04:08:47+00:00 Evommune bets $30m on a VAV1 degrader that could challenge JAK inhibitors, but can it deliver safer autoimmune treatment? EVO301, EVO570, EVO756, Evommune Inc., Greg Moss, HC118, Hinova Pharmaceuticals, Jeegar Patel, Yuanwei Chen https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/iadademstat-shows-95-response-rate-in-leukemia-as-oryzon-genomics-prepares-phase-3-development/ PharmaDeviceNews en 2026-11-04T22:01:01+00:00 Iadademstat shows 95% response rate in leukemia as Oryzon Genomics prepares Phase 3 development ALICE-2, ALICE-3, American Society of Hematology, FRIDA, iadademstat, Oryzon Genomics, U.S. National Cancer Institute https://pharmadevicenews.com/wp-content/uploads/2026/11/Leukemia-treatment-research-e1793829387870.webp https://pharmadevicenews.com/fda-grants-breakthrough-designation-to-daridorexant-following-50-minute-sleep-improvement-in-children/ PharmaDeviceNews en 2026-11-04T19:02:30+00:00 FDA grants breakthrough designation to daridorexant following 50-minute sleep improvement in children Daridorexant, Idorsia, QUVIVIQ, Strasbourg University Hospitals, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/11/Pediatric-sleep-research-e1793818125309.webp https://pharmadevicenews.com/pelareorep-shows-promising-hpv-targeted-immune-activity-as-oncolytics-biotech-advances-cancer-research/ PharmaDeviceNews en 2026-11-04T18:42:34+00:00 Pelareorep shows promising HPV-targeted immune activity as Oncolytics Biotech advances cancer research GOBLET, Oncolytics Biotech, pelareorep, Society for Immunotherapy of Cancer, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/11/Cancer-immunotherapy-research-2-e1793817406414.webp https://pharmadevicenews.com/annamycin-leukemia-trial-progresses-toward-pivotal-dose-selection-after-encouraging-interim-results/ PharmaDeviceNews en 2026-11-04T18:10:00+00:00 Annamycin leukemia trial progresses toward pivotal dose selection after encouraging interim results American Society of Hematology, annamycin, Arensia Exploratory Medicine, MIRACLE trial, Moleculin Biotech, naxtarubicin https://pharmadevicenews.com/wp-content/uploads/2026/11/Myeloid-leukemia-research-e1793815690864.webp